(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 October 2006 (12.10.2006)

PCT

(10) International Publication Number
WO 2006/107962 A3

(51) International Patent Classification:
G01N 33/68 (2006.01)

(21) International Application Number:
PCT/US2006/012493

(22) International Filing Date: 4 April 2006 (04.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/668,404 4 April 2005 (04.04.2005) US

(71) Applicants *(for all designated States except US)*: **BIOGEN IDEC MA INC** [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US). **ELAN PHARMACEUTICALS, INC.** [US/US]; 800 Gateway Boulevard, San Francisco, CA 95080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SUBRAMANYAM, Meena** [US/US]; 3 Corey Avenue, Stoneham, Massachusetts 02180 (US). **AMARAVADI, Lakshmi** [US/US]; 189 South Main Street, Natick, Massachusetts 01760 (US). **WAKSHULL, Eric** [US/US]; 13 Whittaker Lane, Princeton, Massachusetts 01541 (US). **LYNN, Frances** [GB/US]; 157 Lowell Street, Apt. 2, Somerville, MA 02143 (US). **PANZARA, Michael** [US/US]; 73 Bacon Street, Winchester, Massachusetts 01890 (US). **BARBOUR, Robin, McDaid** [US/US]; 250 Normandy Lane, Walnut Creek, CA 94598 (US). **TAYLOR, Julie, Elizabeth** [GB/US]; 1506 7th Avenue, San Francisco, CA 94122 (US).

(74) Agent: **WALLER, Patrick, R H**; Wolf, Greenfield & Sacks, P.C, 600 Atlantic Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
8 March 2007

(48) Date of publication of this corrected version:
19 April 2007

(15) Information about Correction:
see PCT Gazette No. 16/2007 of 19 April 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN

(57) Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab) . A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points . A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.

WO 2006/107962 A3